Triall announces that it has joined the Pistoia Alliance, a not-for-profit members’ organization that works to lower barriers to innovation in the Life Sciences and healthcare research and development (R&D)...Read More
In an increasingly mobile and expeditious world, outbreaks of known or emerging infectious diseases are a real and unavoidable threat. For this reason, it’s vital that we have the right...Read More
Triall announces that its first software solution ‘Verial eTMF’ has successfully passed the pilot stage and is now being onboarded and used in multiple clinical trial consortia. In summer 2019,...Read More
Triall today announces that it has officially partnered with Dizer Capital, a private equity firm focused on startups in the technology sector. The investment provided by Dizer Capital will enable...Read More
As the number of blockchain protocols and platforms has increased significantly over the past 3 years, it can be challenging for enterprises to identify the best for building their blockchain-enabled...Read More
As 2019 comes to an end, the holiday season provides us with time to reflect on what has happened in the past year. It has been an exciting year for...Read More
In part 1 and part 2 of this series, we explained how blockchain technology can be leveraged to enhance the integrity, auditability, and exchange of data in clinical trials. In this article, we will...Read More
In part 1 of this series, we explained how blockchain technology can be leveraged to enhance data integrity, auditability, and traceability in clinical trials. In this article, we dive into other unique...Read More
Allan Bukuya has joined the Triall initiative as Advisor eClinical Solutions. He brings two decades of experience in clinical research and in-depth understanding of the Pharma, CRO and eClinical industries....Read More
Danielle Bradbury will join the Triall initiative as advisor Quality and Compliance. She has over 20 years of experience in clinical research and has extensive knowledge of SOP management, GxP...Read More
